AGRX - Agile Therapeutics Fri 13'th Jan 2017
Stock analysis for Fri 13'th Jan 2017 (Updated daily)
Sell candidate since 2017-01-10
Agile Therapeutics Stock Analysis
Agile Therapeutics fell by -1.95% in the last day, from USD 2.57 to USD 2.52. , and has now fallen 5 day in a row The price has fallen in 8 of the last 10 days and is down by -58.21% for this period. Volume increased in the last day by 156 484 shares, but on falling prices. This is may be an early warning and risk is increased slightly for the next couple of days. In total there were 564 873 shares were bought and sold for approximately USD 1.42 million.
Agile Therapeutics lays in the lower of a very wide and strong falling trend in the short term, and this will normally pose a very good buying opportunity. A break down the bottom trend line at USD 2.16 will firstly indicate a stronger fall rate. Given the current short-term trend, the stock is expected to fall -36.8% during the next 3 months and, with 90% probability will hold a price between USD 1.36 and USD 4.06 at the end of this period.
There are few to none technical positive signals at the moment. Agile Therapeutics holds sales signals from both short- and long-term moving averages. In addition, there is a general sales signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up there will be some resistance from the lines at USD 2.64 and USD 5.68. A break-up above any of these levels will issue buy signals. A sales signal was issued from a pivot top point on Monday January 09, 2017, which indicates further falls until a new bottom pivot has been found. Agile Therapeutics gained volume on the last day, but on falling prices. In technical terms this is called divergence and may be an early warning. In some cases, increasing volume on falling prices may be considered positive, but that is mainly in typical "sell-off's".
Relative Strength Index (RSI)
RSI14 is 7 and the stock is extremely oversold on RSI14, but some stocks may continue to fall despite the high chance of a correction up. The low RSI lowers the general risk and the stock should be considered if other technical requirements like liquidity and risk-reward are meet.
Support & Resistance
There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days. On the upside the stock meets some resistance just above today's level from accumulated volume at USD 2.63, USD 2.69 and USD 2.79.
The stock is about to test the resistance from accumulated volume at USD 2.63 and this may cause the stock to take a minor break or get into a more sideways move for a few days.
This stock may move much during a day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved USD 0.17 between high and low, or 6.91%. For the last week, the stock has had a daily average volatility of 12.35%.
Agile Therapeutics is overbought on RSI14 (7). Some stocks may go long and hard while being overbought on RSI, but overbought increases the general risk as higher volatility could be expected, and at some level thge stock will have a reaction back to gain new strength.
Our recommended stoploss: We hold a sell evaluation for this stock. No stop-loss set.
Agile Therapeutics holds several negative signals and is within a very wide and strong falling trend, so we believe it will still perform weak in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.